TrialArthritis research & therapy2017

A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA®) to the reference product (Humira®) in patients with active rheumatoid arthritis.

Ahmadreza Jamshidi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.